RT Journal Article
T1 Cancer Stem Cells in Soft-Tissue Sarcomas
A1 Martínez-Delgado, Paula
A1 Lacerenza, Serena
A1 Obrador-Hevia, Antonia
A1 Lopez-Alvarez, Maria
A1 Mondaza-Hernandez, José L.
A1 Blanco-Alcaina, Elena
A1 Sanchez-Bustos, Paloma
A1 Hindi, Nadia
A1 Moura, David S.
A1 Martin-Broto, Javier
K1 Cancer stem cells
K1 Tumor-initiating cells
K1 Soft-tissue sarcoma
K1 Chemotherapy resistance
K1 Stemness
K1 Tumor heterogeneity
K1 Genetic and epigenetic plasticity
K1 Células madre neoplásicas
K1 Sarcoma
AB Soft tissue sarcomas (STS) are a rare group of mesenchymal solid tumors with heterogeneous genetic profiles and clinical features. Systemic chemotherapy is the backbone treatment for advanced STS; however, STS frequently acquire resistance to standard therapies, which highlights the need to improve treatments and identify novel therapeutic targets. Increases in the knowledge of the molecular pathways that drive sarcomas have brought to light different molecular alterations that cause tumor initiation and progression. These findings have triggered a breakthrough of targeted therapies that are being assessed in clinical trials. Cancer stem cells (CSCs) exhibit mesenchymal stem cell (MSC) features and represent a subpopulation of tumor cells that play an important role in tumor progression, chemotherapy resistance, recurrence and metastasis. In fact, CSCs phenotypes have been identified in sarcomas, allied to drug resistance and tumorigenesis. Herein, we will review the published evidence of CSCs in STS, discussing the molecular characteristic of CSCs, the commonly used isolation techniques and the new possibilities of targeting CSCs as a way to improve STS treatment and consequently patient outcome.
PB MDPI
YR 2020
FD 2020-06-10
LK http://hdl.handle.net/10668/3711
UL http://hdl.handle.net/10668/3711
LA en
NO Martínez-Delgado P, Lacerenza S, Obrador-Hevia A, Lopez-Alvarez M, Mondaza-Hernandez JL, Blanco-Alcaina E, et al. Cancer Stem Cells in Soft-Tissue Sarcomas. Cells. 2020 Jun 10;9(6):1449
DS RISalud
RD Apr 7, 2025